{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T15:27:24Z","timestamp":1786116444095,"version":"build-2736575974"},"reference-count":27,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T00:00:00Z","timestamp":1785974400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:p>Stathmin 1 (STMN1) is a cytosolic phosphoprotein involved in microtubule dynamics, mitotic progression and cytoskeleton-dependent cellular behaviour. In multiple human malignancies, dysregulated STMN1 expression has been associated with aggressive clinicopathological features, adverse outcomes and, in selected settings, potential therapeutic vulnerability. Its significance in neuroendocrine neoplasms (NENs), however, has not been critically synthesised across anatomical sites. This narrative review examined the available literature on STMN1 in NENs across pulmonary, gastroenteropancreatic, adrenal, cutaneous, pituitary and thyroid settings, with the specific aim of mapping site-specific expression patterns and appraising whether reported associations with aggressive clinicopathological features were descriptive, independently validated, or functionally supported. A literature search was conducted in PubMed, Web of Science, and Scopus from inception to 25 January 2026. Twelve original studies met the inclusion criteria and were narratively synthesised. The available evidence indicates that STMN1 is not a uniform marker of neuroendocrine differentiation across tumour types, but rather a context-dependent signal more often associated with proliferative activity, high-grade morphology and malignant behaviour. The strongest evidence currently derives from pulmonary neuroendocrine neoplasms, where STMN1 has shown diagnostic utility in tissue and bronchoalveolar lavage and where preclinical targeting data are available. Outside the lung, however, the literature is limited and methodologically heterogeneous, and the evidentiary weight varies from descriptive expression studies to functional preclinical observations. Overall, STMN1 emerges as a recurrent molecular signal in several NEN settings, particularly in aggressive and high-grade disease contexts. Its causal biological relevance and clinical value, including potential implications for treatment sensitivity and tumour dissemination, remain to be demonstrated in studies specifically designed for prognostic and therapeutic validation. Current therapeutic evidence remains preclinical and should be regarded as hypothesis-generating rather than clinically actionable.<\/jats:p>","DOI":"10.3389\/fendo.2026.1846997","type":"journal-article","created":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T10:19:05Z","timestamp":1786011545000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Stathmin 1 across neuroendocrine neoplasms: biological, pathological and translational insights"],"prefix":"10.3389","volume":"17","author":[{"given":"Anna","family":"La Salvia","sequence":"first","affiliation":[{"name":"National Center for Drug Research and Evaluation, National Institute of Health (ISS)","place":["Rome, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Tanca","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences, University of Sassari","place":["Sassari, Italy"]},{"name":"Unit of Microbiology and Virology, University Hospital of Sassari","place":["Sassari, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Germano","family":"Gaudenzi","sequence":"additional","affiliation":[{"name":"Laboratory of Geriatric and Oncologic Neuroendocrinology Research, IRCCS, Istituto Auxologico Italiano, Cusano Milanino","place":["Milan, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Pecora","sequence":"additional","affiliation":[{"name":"Endocrinology Unit, Department of Clinical and Molecular Medicine, The European Neuroendocrine Tumor Society (ENETS) Center of Excellence, Sant\u2019Andrea Hospital, Sapienza University of Rome","place":["Rome, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antongiulio","family":"Faggiano","sequence":"additional","affiliation":[{"name":"Endocrinology Unit, Department of Clinical and Molecular Medicine, The European Neuroendocrine Tumor Society (ENETS) Center of Excellence, Sant\u2019Andrea Hospital, Sapienza University of Rome","place":["Rome, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Vitale","sequence":"additional","affiliation":[{"name":"Laboratory of Geriatric and Oncologic Neuroendocrinology Research, IRCCS, Istituto Auxologico Italiano, Cusano Milanino","place":["Milan, Italy"]},{"name":"Department of Medical Biotechnology and Translational Medicine, University of Milan","place":["Milan, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo","family":"Cossu-Rocca","sequence":"additional","affiliation":[{"name":"Department of Medicine, Surgery and Pharmacy, University of Sassari","place":["Sassari, Italy"]},{"name":"Surgical Pathology Unit, \u201cGiovanni Paolo II\u201d Hospital, Local Health Authority (ASL) Gallura","place":["Olbia, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Fanciulli","sequence":"additional","affiliation":[{"name":"Department of Medicine, Surgery and Pharmacy, University of Sassari - University Hospital (AOU) of Sassari","place":["Sassari, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,6]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1038\/s41379-018-0110-y","article-title":"A common classification framework for neuroendocrine neoplasms: an International Agency for Research on Cancer (IARC) and World Health Organization (WHO) expert consensus proposal","volume":"31","author":"Rindi","year":"2018","journal-title":"Mod Pathol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1007\/s12022-022-09708-2","article-title":"Overview of the 2022 WHO classification of neuroendocrine neoplasms","volume":"33","author":"Rindi","year":"2022","journal-title":"Endocr Pathol"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.03.304","article-title":"Gastroenteropancreatic neuroendocrine neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"31","author":"Pavel","year":"2020","journal-title":"Ann Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)00186-2","article-title":"Consensus on biomarkers for neuroendocrine tumour disease","volume":"16","author":"Oberg","year":"2015","journal-title":"Lancet Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1586\/14737140.8.9.1461","article-title":"Stathmin 1: a novel therapeutic target for anticancer activity","volume":"8","author":"Rana","year":"2008","journal-title":"Expert Rev Anticancer Ther"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1309958110","article-title":"Mechanism for the catastrophe-promoting activity of the microtubule destabilizer Op18\/stathmin","volume":"110","author":"Gupta","year":"2013","journal-title":"Proc Natl Acad Sci USA"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1177\/1724600819837210","article-title":"Association of STMN1 with survival in solid tumors: a systematic review and meta-analysis","volume":"34","author":"Zhang","year":"2019","journal-title":"Int J Biol Markers"},{"key":"B8","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1038\/s41419-022-04625-y","article-title":"Stathmin 1 is a biomarker for diagnosis of microvascular invasion to predict prognosis of early hepatocellular carcinoma","volume":"13","author":"Cai","year":"2022","journal-title":"Cell Death Dis"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellsig.2023.110775","article-title":"STMN1 in human cancers: role, function and potential therapy sensitizer","volume":"109","author":"Liu","year":"2023","journal-title":"Cell Signal"},{"key":"B10","volume-title":"Urinary and Male Genital Tumours","year":"2022"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1016\/j.jprot.2010.12.001","article-title":"Proteomic analysis of archival lung neuroendocrine tumour samples","volume":"74","author":"Tanca","year":"2011","journal-title":"J Proteomics"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.5603\/FHC.2012.0050","article-title":"Secretomic analysis of large cell lung cancer cell lines using 2DE and MS","volume":"50","author":"Yousefi","year":"2012","journal-title":"Folia Histochem Cytobiol"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0000000000000090","article-title":"Discovery of new membrane-associated proteins overexpressed in small-cell lung cancer","volume":"9","author":"Ocak","year":"2014","journal-title":"J Thorac Oncol"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0000000000000282","article-title":"A new biomarker panel in bronchoalveolar lavage for lung cancer diagnosis","volume":"9","author":"Uribarri","year":"2014","journal-title":"J Thorac Oncol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1016\/j.athoracsur.2019.02.040","article-title":"Stathmin-1 is a useful diagnostic marker for high-grade lung neuroendocrine tumours","volume":"108","author":"Shimizu","year":"2019","journal-title":"Ann Thorac Surg"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.70179","article-title":"Novel therapeutic strategy targeting STMN1 using chlorambucil-conjugated pyrrole-imidazole polyamide in small cell lung cancer","volume":"158","author":"Yoshikawa","year":"2026","journal-title":"Int J Cancer"},{"key":"B17","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1007\/s13277-014-2629-y","article-title":"Stathmin in pancreatic neuroendocrine neoplasms: a marker of proliferation and PI3K signalling","volume":"36","author":"Schimmack","year":"2015","journal-title":"Tumour Biol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/s12022-008-9028-0","article-title":"Stathmin expression in pheochromocytomas, paragangliomas, and in other endocrine tumours","volume":"19","author":"Sadow","year":"2008","journal-title":"Endocr Pathol"},{"key":"B19","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1055\/s-0029-1202789","article-title":"Stathmin as a marker for Malignancy in pheochromocytomas","volume":"118","author":"Bj\u00f6rklund","year":"2010","journal-title":"Exp Clin Endocrinol Diabetes"},{"key":"B20","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/S1015-9584(11)60013-4","article-title":"Stathmin immunoreactivity in phaeochromocytomas and paragangliomas: differential expression between benign and Malignant neoplasms","volume":"34","author":"Lin","year":"2011","journal-title":"Asian J Surg"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1186\/1755-8794-5-48","article-title":"Integrative analysis of neuroblastoma and pheochromocytoma genomics data","volume":"5","author":"Szab\u00f3","year":"2012","journal-title":"BMC Med Genomics"},{"key":"B22","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1128\/JVI.02317-14","article-title":"Merkel cell polyomavirus small T antigen mediates microtubule destabilisation to promote cell motility and migration","volume":"89","author":"Knight","year":"2015","journal-title":"J Virol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1007\/s12672-025-01754-6","article-title":"Stathmin 1 expression in neuroendocrine and proliferating prostate cancer","volume":"16","author":"Shi","year":"2025","journal-title":"Discover Oncol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-017-6083-0","article-title":"High STMN1 expression is associated with cancer progression and chemo-resistance in lung squamous cell carcinoma","volume":"24","author":"Bao","year":"2017","journal-title":"Ann Surg Oncol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12113323","article-title":"Mechanisms of taxane resistance","volume":"12","author":"Maloney","year":"2020","journal-title":"Cancers (Basel)"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1007\/BF01076766","article-title":"The phosphorylation of stathmin by MAP kinase","author":"Leighton","year":"1993","journal-title":"Mol Cell Biochem"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-12-1158","article-title":"Inhibition of stathmin1 accelerates the metastatic process","volume":"72","author":"Williams","year":"2012","journal-title":"Cancer Res"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1846997\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T10:19:06Z","timestamp":1786011546000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1846997\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,6]]},"references-count":27,"alternative-id":["10.3389\/fendo.2026.1846997"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2026.1846997","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,6]]},"article-number":"1846997"}}